A Phase II Trial of Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A)Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

Trial Profile

A Phase II Trial of Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A)Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 17 May 2017

At a glance

  • Drugs Pazopanib (Primary) ; Topotecan (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Dec 2015 Status changed from recruiting to not yet recruiting as per ClinicalTrials.gov record.
    • 23 Dec 2015 Planned primary completion date changed from 1 Nov 2020 to 1 Oct 2019 as per ClinicalTrials.gov record
    • 23 Dec 2015 Planned initiation date changed from 1 Dec 2013 to 1 Dec 2015 as per ClinicalTrials.gov record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top